Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

f completion of enrolment for the Phase II AGW trial of Topical Interferon Alpha-2b; the timing of a future Phase I/II clinical study for L-DOS47 in Poland; sufficiency of the Company's cash reserves and expected cash flow from operations; and other information in future periods, which statements and information can be identified by the use of forward-looking terminology such as "plans", "expected", "intends"; "estimates", "next", "anticipated", "developing", "will" or variations thereon, or comparable terminology referring to future events or results. Although Helix believes that the expectations reflected in such forward-looking statements and information are reasonable, such statements and information involve risks and uncertainties, and undue reliance should not be placed on such statements and information. Certain material factors or assumptions are applied in making forward-looking statements and providing forward-looking information, including, but not limited to, patient recruitment rates and the timely and successful completion of ongoing clinical trials, GMP manufacturing and other activities; the timely provision of services by third parties; future revenue, costs and regulatory approvals. Important factors that could cause actual results to differ materially from these forward-looking statements and information include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse impact on the Company and its ability to continue, or if not obtained in a timely manner, may result in the Company's having to discontinue or delay one or more of its product development programs or other initiatives; uncertainty whether Topical Interferon Alpha-2b or L-DOS47 will be successfully developed and commercialized as a drug or at all; the risk that the FDA is not bound by its pre-IND meetings; uncertainty whether any of the timelines mentione
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Columbia , May 5, 2015  InMed ... clinical stage biopharmaceutical company that specializes in developing ... former GW Pharmaceuticals financier, investor, and Non-Executive Director, ... InMed as Strategic Advisor with primary responsibility for ... role, Mr. Mountford will leverage his previous success ...
(Date:5/4/2015)... VANCOUVER, British Columbia , May 4, ... announced today that it will report its first quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
(Date:5/4/2015)...  Amgen (NASDAQ: AMGN ) will present at the ... on Thursday, May 7, 2015, at the InterContinental in ... vice president of Global Commercial Operations at Amgen, will present ... accessed from the Events Calendar on Amgen,s website, www.amgen.com ... be available on Amgen,s website for 90 days following the ...
Breaking Medicine Technology:InMed Engages Peter Mountford as Strategic Advisor 2InMed Engages Peter Mountford as Strategic Advisor 3InMed Engages Peter Mountford as Strategic Advisor 4Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference 2
... 10, 2010 Mylan Inc. (Nasdaq: MYL ... conversion rate applicable to its 6.50% Mandatory Convertible Preferred ... common stock of the company effective as of November ... the governing provisions of the company,s Amended and Restated ...
... Pharmaxis, a global specialty pharmaceutical company focused on therapeutic ... (mannitol inhalation powder) Bronchial Challenge Test Kit, at the ... Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ. ... Drug Administration (FDA) on October 5, 2010, ARIDOL is ...
Cached Medicine Technology:Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology 2Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology 3Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology 4Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology 5
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Gloria M. Betancourt as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... present Gloria with this important honor," said NAPW President ...
(Date:5/4/2015)... 2015 Every Friday afternoon at A ... in Southwest Michigan, patients and staff gather in the ... the rehabilitation program and to gain encouragement and inspiration ... , One by one, those patients who have completed ... their certificates and to share a bit about their ...
(Date:5/4/2015)... 2015 Global Vision, the industry ... today announced that it will showcase Proofware at ... Center, in Nashville Tennessee, May 04 and May ... true all-in-one we-based packaging inspection suite, giving enterprise-wide ... of their brand copy and artwork. Proofware offers ...
(Date:5/4/2015)... Leonardo J. Lozada, M.D., Saint Luke’s ... and William C. Daniel, M.D., Saint Luke’s Health System ... from the Secretary of the Air Force to attend ... Air War College, Maxwell Air Force Base, Alabama. The ... senior U.S. and international officers and their civilian counterparts ...
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2
... announced the approval of a new antifungal drug, for ... new drug called Eraxis, // is indicated in the ... ,The improved performance of Eraxis compared to ... have supported the approval. The drug can also be ...
... quite a trend setter of sorts. Now, BT Offices and ... // that smoking is banned in the BT premises as ... 26. Importantly, this move might encourage “anti-smoking” initiatives in other ... this announcement, which will surely set a precedent. Now this ...
... sex determination gene, that plays a crucial role in deciding ... (embryo with SRY gene develops into a male), could explain ... SRY protein, required for formation of testes is also produced ... Prince Henry's Institute and University of California. ,The ...
... infected by bird flu in northwestern Germany has been steadily ... // About 2 of the 103 cases were identified outside ... and troops have been involved in collection of carcasses. ... harbor the deadly virus. The Institute for Animal Health in ...
... reduce the harmful effects caused to babies by mothers who ... University. Foetal Alcohol Syndrome (FAS) results in mental retardation in ... ,The reserachers say that a drug called nicotinamide ... particular syndrome. The researchers arrived at this conclusion after successful ...
... foundation stone to construct a world-class cancer hospital and research ... at Rajarhat,// at the cost of Rs. 1.2 billion. ... would come up on a 10-acre plot, West Bengal Chief ... after laying the foundation stone for the project scheduled to ...
Cached Medicine News:Health News:Sex Determination Gene Blamed For High Incidence Of Parkinson’s In Me 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: